Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis
The Journal of Clinical Endocrinology & Metabolism · 21.01.2026 · 111 (2) · 405-417
DOI: 10.1210/clinem/dgaf399 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.07.2025. Verfasst von Javier Bodoque-Cubas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rovira i Virgili University, Faculty of Medicine, PhD School of Biomedical Sciences, Tarragona, Catalonia 43002, Spain. Hauptthemen laut MEDLINE: Thyroid Nodule, Artificial Intelligence. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Objective
The increasing incidence of thyroid nodules (TNs) raises concerns about overdiagnosis and overtreatment. This study evaluates the clinical and economic impact of KOIOS, a Food and Drug Administration-approved artificial intelligence (AI) tool for the management of TN.
Methods
A retrospective analysis was conducted on 176 patients who underwent thyroid surgery between May 2022 and November 2024. Ultrasound images were evaluated independently by an expert and novice operators using the American College of Radiology Thyroid Imaging Reporting and Data System, while KOIOS provided AI-adapted risk stratification. Sensitivity, specificity, and receiver operating (ROC) curve analysis were performed. The incremental cost-effectiveness ratio (ICER) was defined based on the number of optimal care interventions (fine-needle aspiration biopsies and thyroid surgeries). Both deterministic and probabilistic sensitivity analyses were conducted to evaluate model robustness.
Results
KOIOS AI demonstrated similar diagnostic performance to the expert operator [area under the curve (AUC): 0.794, 95% confidence interval (CI): 0.718-0.871 vs 0.784, 95% CI: 0.706-0.861; P = .754] and significantly outperformed the novice operator (AUC: 0.619, 95% CI: 0.526-0.711; P < .001). ICER analysis estimated the cost per additional optimal care decision at −€8085.56, indicating KOIOS as a dominant and cost-saving strategy when considering a third-party payer perspective over a 1-year horizon. Deterministic sensitivity analysis identified surgical costs as the main drivers of variability, while probabilistic analysis consistently favored KOIOS as the optimal strategy.
Conclusion
KOIOS AI is a cost-effective alternative, particularly in reducing overdiagnosis and overtreatment for benign TNs. Prospective, real-life studies are needed to validate these findings and explore long-term implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rovira i Virgili University, Faculty of Medicine, PhD School of Biomedical Sciences, Tarragona, Catalonia 43002, Spain.
- Endocrinology and Nutrition Department, Verge de la Cinta Hospital, Tortosa, Catalonia 43500, Spain.
- Research Support Unit-Terres de l'Ebre, Institut Català de la Salut, Fundació Institut Universitari per a la Recerca a L'Atenció Primària de Salut Jordi Gol I Gurina, Tortosa 43500, Spain.
- Nursery School-Terres de l´Ebre Campus, Rovira I Virgili Universtiy, Tortosa, Catalonia 43500, Spain.
- Department of Medicine, University of Valencia, Valencia, Valencian Community 46010, Spain.
- Department of Endocrinology and Nutrition, Hospital Clínico Universitario of Valencia, Valencia, Valencian Community 46010, Spain.
ORCID-Profile: Javier Bodoque-Cubas, José Fernández-Sáez, Sergio Martínez-Hervás, María José Pérez-Lacasta, Misericòrdia Carles-Lavila, Raquel María Pallarés-Gasulla, Juan José Salazar-González, José Vicente Gil-Boix, Marcel la Miret-Llauradó, Anna Aulinas-Masó, Iñaki Argüelles-Jiménez, Santiago Tofé-Povedano
Zitieren
APA
Bodoque-Cubas, J., Fernández-Sáez, J., Martínez-Hervás, S., Pérez-Lacasta, M. J., Carles-Lavila, M., Pallarés-Gasulla, R. M., Salazar-González, J. J., Gil-Boix, J. V., Miret-Llauradó, M., Aulinas-Masó, A., Argüelles-Jiménez, I., & Tofé-Povedano, S. (2026). Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis. The Journal of Clinical Endocrinology & Metabolism, 111(2), 405-417. https://doi.org/10.1210/clinem/dgaf399
Vancouver
Bodoque-Cubas J, Fernández-Sáez J, Martínez-Hervás S, Pérez-Lacasta MJ, Carles-Lavila M, Pallarés-Gasulla RM, et al. Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis. The Journal of Clinical Endocrinology & Metabolism. 2026;111(2):405-417. doi:10.1210/clinem/dgaf399
BibTeX
@article{BodoqueCubas2026,
author = {Bodoque-Cubas, Javier and Fernández-Sáez, José and Martínez-Hervás, Sergio and Pérez-Lacasta, María José and Carles-Lavila, Misericòrdia and Pallarés-Gasulla, Raquel María and Salazar-González, Juan José and Gil-Boix, José Vicente and Miret-Llauradó, Marcel la and Aulinas-Masó, Anna and Argüelles-Jiménez, Iñaki and Tofé-Povedano, Santiago},
title = {Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {2},
pages = {405--417},
doi = {10.1210/clinem/dgaf399}
}
EUVIMED